Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Samsung Electronics | Eli Lilly and Company | ASM International | |
|---|---|---|---|
| Moat rating | narrow Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247). | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow The 2025 annual report (published 2026-03-12) says 'ASM is the leader in the fast-growing single-wafer ALD market – with a market share of 55%+ (ASM estimate, Investor Day 2025)'. It says ASM 'maintained leadership with our market share surpassing 55%' as the industry moved from FinFET to GAA. And it says that 'Based on the breadth of our R&D engagements and critical production-tool-of-record (PTOR) selections already secured in 2025, we expect to at least maintain our market share' into the 1.4nm node. The Q2 2026 results (https://www.asm.com/media/y0mkxj21/20260728-asm-reports-second-quarter-2026-results.pdf) say the 1.4nm node is on track for its first meaningful contribution in the second half of 2026, 'reflecting increased market share gains in both ALD and Epi'. 2025 gross margin was 51.8%. That is a strong, profitable position, but every share figure behind it is ASM's own estimate or expectation, and no independent share source supports it, so the rating is narrow rather than wide. The exposures also weigh: the five largest customers took about 53.6% of 2025 revenue and China more than 30%, and the report describes the main competitors as 'much larger companies from the United States and Asia'. |
| Moat type | cost scale The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html). | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The report grounds the ALD lead in accumulated process know-how and patents rather than unit cost: 'ASM has the broadest portfolio of ALD products with innovative ALD reactor designs. Our strength in chemistries and applications using new materials means our customers can meet advanced node technology challenges.' It also cites a LexisNexis PatentSight study finding that 'ASM holds a strong and impactful patent portfolio on its core strength of ALD as measured by both Competitive Impact and Patent Asset Index'. Switching friction reinforces this. Tools enter fabs through PTOR selection, the report notes that 'Failing a customer during a production ramp could create significant problems for them', and installed systems are supported 'with a view to having them in production 24/7 for 20+ years'. But ASM wins those PTOR slots node by node on process capability, which makes IP the primary source. |
| Leadership | co leader Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead). | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader In single-wafer ALD, which is more than half of equipment sales, the report calls ASM 'the leader' with a 55%+ share. That share is ASM's own estimate; the Investor Day 2025 deck (https://www.asm.com/media/m3jhkm12/asm_investor_day_2025.pdf) sources it to 'ASM internal analysis and TechInsights'. With no independent share source, the band is held at co_leader rather than clear_leader. ASM does not lead every line: 'ASM has the number two share in the Epi equipment market', and in PECVD and vertical furnaces it is 'focused on niche portions of the market'. |
| Pricing power | moderate Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate Gross margin rose from 50.5% to 51.8% in 2025 and was 51.9% in Q2 2026. But the report attributes the 2025 gain to 'a very strong mix, including a continued solid contribution from the Chinese market' and to efficiency programs, not to price. It targets a range of 47% to 51% for 2026-2030, and the Q2 2026 release expects full-year 2026 gross margin 'to be around 51%'. Buyers are concentrated: the 10 largest customers were about 72.3% of 2025 revenue, the five largest about 53.6%, and two customers each contributed more than 10% of total revenue. |
| Summary | Samsung Electronics is the world's largest memory maker and a vertically integrated device company. In Q1 2026 it was #1 in DRAM (38.5% revenue share) and #1 in NAND (31.6%), and in Q2 2026 it retook #1 in global smartphones at 24% share. The AI-datacenter memory shortage produced record results: Q2 2026 company revenue of KRW 171.5 trillion and an all-time-high operating profit of KRW 89.5 trillion, with server memory reaching a record share of the sales mix and HBM4E samples shipped to major customers (Samsung Newsroom). The caveats that keep the moat narrow: the profit pool is a price cycle, not a structural annuity; SK hynix leads the highest-value HBM segment by bit-shipment mix; and Samsung Foundry, at 6.5% share versus TSMC's ~72%, remains a distant second in leading-edge logic despite expanding 2nm design wins. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | ASM International, headquartered in the Netherlands, makes wafer-processing equipment with a focus on deposition: single-wafer ALD, silicon epitaxy, PECVD, vertical furnaces, silicon-carbide epitaxy and, since its acquisition of Axus in December 2025, CMP. Spares & Services made up 23% of 2025 revenue. ALD is the core. It was the largest product line, 'clearly accounting for more than half of our equipment sales', and ASM estimates its single-wafer ALD share at 55%+. The report frames ALD as increasingly necessary, saying 'ALD is the only deposition technology capable of meeting the coverage and film-property requirements for complex 3D structures', and expects ALD layers to grow in GAA transistor stacks, backside-power architectures and future 4F² DRAM. Epitaxy is the second-largest line: the report says ASM holds the number two share there and lifted its leading-edge share from 12% in 2020 to 25% in 2024, both by ASM's own figures. 2025 revenue reached a record €3.2 billion at a gross margin of 51.8%; per the Q2 2026 results, Q2 2026 revenue was €1,003 million at 51.9%. The exposures are customer concentration (the five largest customers were about 53.6% of 2025 revenue), geography (Asia was 80% of revenue and China more than 30%), and export restrictions that the report says are 'impacting our ability to sell and service systems in certain jurisdictions and for certain customers'. |
| Chain position | Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Upstream wafer-fab-equipment supplier to logic/foundry and memory chipmakers. 'The leading-edge logic/foundry market was the main growth driver for ASM, on the back of 2nm investments' in 2025, advanced-node DRAM was the largest part of memory sales, and Asia was 80% of revenue. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. |